Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 2:42 PM
Ignite Modification Date:
2025-12-24 @ 2:42 PM
NCT ID:
NCT01680159
Eligibility Criteria:
Inclusion Criteria:
* Patients who have already been diagnosed as having plaque psoriasis, psoriatic arthritis, pustular psoriasis (excluding a localized), or psoriatic erythroderma.
* Patients in whom effect of the treatment was confirmed for a certain period after the start of administration of Remicade® at 5 mg/kg at every 8 weeks but decreased thereafter.
Exclusion Criteria:
* Patients who have guttate psoriasis.
* Patients who have drug-induced psoriasis
* Patients who have previously used any other biological products than infliximab.
* Patients who have a concomitant diagnosis, or a history within 6 months prior to provisional enrollment, of serious infections that need hospitalization.
* Patients who have a concomitant diagnosis, or a history within 6 months prior to provisional enrollment, of opportunistic infections
* Female patients who are pregnant, breast-feeding, or possibly pregnant.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
16 Years
Maximum Age:
75 Years
Study:
NCT01680159
Study Brief:
Protocol Section:
NCT01680159